![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Kainate subtype glutamate receptors (KARs) are ligand-gated cationic channels of the glutamate receptor family. Recent development in the pharmacology of kainate receptors has resulted in the emergence of some selective potent agonists, antagonists and modulators. These KAR ligands have potential therapeutic applications in treating a variety of neuronal diseases as well as pain, epilepsy, cancer and obesity. This article covers the patents filed for KAR ligands dating from 2000 to the third quarter of 2003.